Clinical Evidence

Efficacy and safety have been well documented in a number of peer-reviewed studies since HFCC technology was first introduced. Learn about the growing body of evidence supporting the advantages of HFCC vest therapy – and hear the personal stories of those who experience inCourage Airway Clearance Therapy daily.

High Frequency Chest Compression (HFCC) Evidence Summary

Since the introduction of high frequency chest compression (HFCC)/high frequency chest wall oscillation (HFCWO) technology in the early 1990s, efficacy and safety have been well documented in a number of peer-reviewed studies. Results from these studies have yielded a consistent and growing body of evidence supporting the clinical, economic and quality of life advantages of high frequency chest compression (HFCC)/high frequency chest wall oscillation (HFCWO), or vest therapy.

An overview of key findings

  • The inCourage® System meets or exceeds all FDA-mandated safety and efficacy standards.
  • In over 25 studies involving hundreds of patients, HFCC therapy has been proven safe for use by patients with a broad range of acute and chronic conditions.
  • No study has associated a clinically significant adverse event with HFCC therapy.
  • HFCC therapy improved or sustained long-term pulmonary function scores (PFTs)1,2,3
  • Patients requiring airway clearance therapy for mucus removal who used HFCC had a lower incidence of pneumonias, hospitalizations, ICU days.4,5,6
  • HFCC therapy reduced healthcare expenditures.7,8
  • Most patients tolerated and expressed satisfaction with the therapy.
  • In a comparative study, HFCC therapy cleared three times more mucus than chest percussion therapy (CPT).10
  • In comparison studies, triangle waveform pulse therapy (used in the inCourage® System) improved airway secretion clearance by as much as 20% over sine wave systems – and study participants found it easier to breathe during therapy compared to sine wave systems.9

Clinical Trials

Secretion Clearance – The inCourage® System is recognized by the FDA as an airway secretion clearance device. It is intended for patients who are unable to clear airway secretions without external manipulation or therapeutic intervention. Peer-reviewed clinical research studies show that high frequency chest compression (HFCC)/high frequency chest wall oscillation (HFCWO) therapy is superior or equivalent to professionally administered chest physiotherapy (CPT). Two large randomized controlled trials (RCTs) showed volume for volume mucus clearance results superior to professionally administered CPT.2,10

Pulmonary Function – Decreasing lung function correlates closely with increased frequency and severity of respiratory illness, hospitalization, medical care costs and diminished quality of life. Effective airway secretion clearance therapy can help preserve lung function, slow the progression of lung disease and avoid or reduce the need for more intensive therapy such as intravenous antibiotics. Quality of life can also improve with reduced breathlessness, better exercise tolerance and a greater ability for daily activities.

Long-term and short-term studies show that high frequency chest compression (HFCC)/high frequency chest wall oscillation (HFCWO) helps sustain or improve pulmonary function. Peer-reviewed clinical research studies show that HFCC/HFCWO systems provide therapy that is superior or equivalent to professionally administered chest physiotherapy (CPT).

In a long-term study comparing chest physiotherapy (CPT) to high frequency chest compression (HFCC) in cystic fibrosis (CF) patients, 94% showed positive improvements for percent predicted forced vital capacity (FVC) and forced expiratory volume in one minute (FEV1) after two years of HFCC therapy. Most showed clinical improvement. The long – term FVC and FEV1 gains shown in this study are unprecedented.1

In a crossover study comparing the volume of mucus cleared using HFCC vs. CPT, HFCC therapy was shown to be more effective than standard CPT for all outcomes measured including effects on pulmonary function.2

In a short-term evaluation of the effect of HFCC/HFCWO on pulmonary function compared with chest physiotherapy (CPT) or alternative therapies in 54 CF patients, FEV1 improved significantly after an average of 3 months of HFCC/HFCWO treatment.1

CPTvsHFCC_Graph2